S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
How to Know Which AI Company to Invest In… and When (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
The only accurate crypto trading system I know … (Ad)
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
Free Trial

Aprea Therapeutics (APRE) Stock Forecast & Price Target

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)
Free APRE Stock Alerts
$5.70
-0.20 (-3.39%)
(As of 04/16/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Aprea Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

$15.50
171.93% Upside
High Forecast$20.00
Average Forecast$15.50
Low Forecast$11.00
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.50$14.50$14.50$60.00
Predicted Upside171.93% Upside292.42% Upside292.42% Upside305.38% Upside
Get Aprea Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.

APRE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

APRE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Aprea Therapeutics Stock vs. The Competition

TypeAprea TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside171.93% Upside931.32% Upside11.92% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/27/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$9.00 ➝ $11.00+85.81%
3/26/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$20.00+236.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:50 PM ET.

APRE Price Target - Frequently Asked Questions

What is Aprea Therapeutics's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Aprea Therapeutics stock is Buy based on the current 2 buy ratings for APRE. The average twelve-month price prediction for Aprea Therapeutics is $15.50 with a high price target of $20.00 and a low price target of $11.00. Learn more on APRE's analyst rating history.

Do Wall Street analysts like Aprea Therapeutics more than its competitors?

Analysts like Aprea Therapeutics more than other Medical companies. The consensus rating for Aprea Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how APRE compares to other companies.

Does Aprea Therapeutics's stock price have much upside?

According to analysts, Aprea Therapeutics's stock has a predicted upside of 161.38% based on their 12-month stock forecasts.

What analysts cover Aprea Therapeutics?

Aprea Therapeutics has been rated by HC Wainwright, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:APRE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
[BUY ALERT] Our #1 A.I. Stock for April
Behind the Markets